Bone Accrual and Hormones in Response to Lactation
1 other identifier
observational
141
1 country
1
Brief Summary
This is a prospective observational trial of healthy postpartum women to investigate changes in bone density and markers of bone turnover during lactation. The study hypothesis is that women who breast-feed 5 months or more will lose bone density and subsequently regain the bone density after weaning. This study seeks to define determinants of the regain in bone density.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2003
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2003
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2010
CompletedFirst Submitted
Initial submission to the registry
March 22, 2012
CompletedFirst Posted
Study publicly available on registry
March 26, 2012
CompletedNovember 30, 2023
November 1, 2023
7.6 years
March 22, 2012
November 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The association of change in bone density and change in IGF-1 axis hormones during lactation and weaning
~Two Years
Secondary Outcomes (1)
The association of changes in bone density and change in bone turnover markers during lactation and weaning.
~Two years
Eligibility Criteria
Postpartum women from outpatient obstetrical/gynecology clinics.
You may qualify if:
- age \>20 at the time of delivery
- singleton pregnancy and
- \<2 prior pregnancies that were \>20 weeks gestation.
You may not qualify if:
- maternal rheumatologic disorders
- maternal anorexia nervosa
- maternal endocrinologic disorders,
- medications known to affect bone density such as corticosteroids, thyroid hormone use, anticonvulsant therapy, bisphosphonates, long-term GnRH agonists use and calcitonin.
- Subsequent pregnancy during the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Virginialead
- University of North Carolinacollaborator
Study Sites (1)
University of North Carolina
Chapel Hill, North Carolina, 27599, United States
Biospecimen
Blood samples.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sue Brown, MD
UVA
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor of Medicine
Study Record Dates
First Submitted
March 22, 2012
First Posted
March 26, 2012
Study Start
January 1, 2003
Primary Completion
August 1, 2010
Study Completion
August 1, 2010
Last Updated
November 30, 2023
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will share
Deidentified IPD may be available by direct request of Principal Investigator.